Orion discontinues deramciclane for GAD

Orion (Espoo, Finland) and partner Pharmacia (PHA) discontinued development of deramciclane to treat general anxiety disorder (GAD) after combined results from three U.S. and European Phase III studies failed to show efficacy. The company said the compound showed efficacy in one of the two European studies last year and that it also showed an anxiolytic effect in preclinical and Phase II trials. Orion said it would consider developing the compound for other indications. ...